Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! Today, we discuss why an advisory committee was not thrilled with Amgen’s data for Lumakras, and Neurocrine Biosciences has a potential blockbuster up its sleeve. Oh, and we’ll be off for Indigenous Peoples’ Day next week and will be back in your inbox Tuesday!
The need-to-know this morning
• Sanofi is exploring an acquisition of Mirati Therapeutics, Bloomberg reported, news that sent the company’s share price up nearly 50%.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect